University of Michigan's newest Peregrine falcons now have official names
The two chicks – one female and one male – will be known as Victoria and Valiant, according to Monday's announcement.
The chicks hatched in May from a nesting box on top of the North Quad. The Michigan Department of Natural Resources then worked with The University Record and the U-M community to help name the chicks.
More than 1,400 suggestions were submitted online, including several suggestions for Victor or Victoria. There was also a noticeable trend in suggested names inspired by the 2016 film "Miss Peregrine's Home for Peculiar Children."
By tradition, the names given to Peregrine falcons hatched on campus have connections to the university or the Ann Arbor region.
Peregrine falcons were nearly extinct, but last summer there were 30 nests confirmed across the state. The birds are now listed as threatened rather than endangered.
Amid that repopulation, Peregrine falcons started to be noticed in southeast Michigan in the early 2000s, including a pair that decided to nest in Burton Tower. Since that turned out not to be an ideal spot for the falcons, the Michigan Department of Natural Resources created other nesting sites in the area.
The one on North Quad is now the only nesting site on campus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported symptoms with excellent safety profile IRVINE, Calif., July 21, 2025--(BUSINESS WIRE)--Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. Key Phase 2 Results Primary Endpoint Achieved: Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to vehicle at Day 28, as assessed by an independent reading center using digital imaging. Rapid Onset and Sustained Efficacy: Significant improvements were observed as early as Day 7 with the highest investigated concentration CBT-004 , with benefits persisting through the 28-day treatment period. Significant Symptom Relief: Both CBT-004 concentrations showed statistically significant improvements in five common patient-reported symptoms including burning/stinging, itching, foreign body sensation, eye discomfort, and pain compared to vehicle. Excellent Safety Profile: No treatment-related adverse events were observed. Most adverse events were mild to moderate. No clinically meaningful changes in visual acuity or intraocular pressure were reported. Addressing a Significant Unmet Medical Need Vascularized pinguecula affects millions of Americans and represents a substantial unmet medical need in ophthalmology. This common, benign conjunctival growth can become problematic when it develops abnormal blood vessels and inflammation, which can lead to persistent redness, irritation, pain, and foreign body sensation. Current management options are limited, with many patients relying on off-label corticosteroids or surgical excision, both of which carry significant limitations and potential complications. Study Design and Results The multicenter, randomized, double-masked, vehicle-controlled Phase 2 study enrolled 88 adult patients with vascularized pinguecula and associated conjunctival hyperemia. Participants were randomized to receive one of two concentrations of CBT-004, or vehicle. The primary endpoint was the change from baseline in conjunctival hyperemia at Day 28, as measured by an independent reading center using standardized digital imaging protocols. Expert Commentary "There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognized key opinion leader in anterior segment disease. "The results from this trial are exciting, as they demonstrate that a targeted, non- steroidal therapy can meaningfully improve both the clinical signs and symptoms that impact patients' quality of life." "As a principal investigator in this study, I was impressed by the consistency and magnitude of improvement in both objective redness and patient-reported discomfort with CBT-004," commented Dr. Sherif El-Harazi, Medical Director at Global Research Management. "The safety profile was excellent, and I believe this therapy could represent a meaningful advance for our patients with vascularized pinguecula." About CBT-004 CBT-004 is a novel, preservative-free topical ophthalmic solution containing a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor (PDGF) receptors. The formulation is specifically designed to reduce abnormal blood vessel growth and inflammation associated with vascularized pinguecula while minimizing potential ocular surface toxicity through its preservative- free composition. Next Steps and Regulatory Strategy Based on these positive Phase 2 results, Cloudbreak Pharma Inc. plans to advance CBT-004 into Phase 3 development and initiate discussions with the U.S. Food and Drug Administration (FDA) to establish the regulatory pathway toward potential approval. The company anticipates providing updates on Phase 3 study design and timing in the coming months. Market Opportunity The vascularized pinguecula market represents a significant commercial opportunity with limited therapeutic options. The prevalence of pinguecula increases with age and UV exposure, affecting a substantial portion of the aging population. With no FDA-approved treatments specifically indicated for this condition, CBT-004 has the potential to become a category-defining therapy in this underserved market. About Cloudbreak Pharma Inc. Cloudbreak Pharma Inc. is a clinical-stage ophthalmology company dedicated to developing innovative therapies for ocular surface diseases with high unmet medical need. The company's pipeline focuses on novel treatments targeting inflammation, vascularization, and other pathological processes affecting the ocular surface. Cloudbreak is committed to improving outcomes for patients with challenging eye conditions through scientifically-driven therapeutic development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential therapeutic benefits of CBT-004, the company's clinical development plans, regulatory strategy, and market opportunity. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause actual results to differ include, but are not limited to, the uncertainty of clinical trial results, regulatory approval processes, competitive developments, and other risks detailed in the company's filings. The company undertakes no obligation to update these forward-looking statements except as required by law. Please note that the information contained in this press release may not be complete. For further details about Cloudbreak Pharma Inc., and our drug candidates, please refer to our company's website (at View source version on Contacts Contact Information: Cloudbreak Pharma media@ Web: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Study reveals this type of exercise lowers your biological age by 9 years
When you buy through links on our articles, Future and its syndication partners may earn a commission. If you're looking to pause time, we've got good news — when it comes to biological aging, that's the aging process that happens inside your cells, sweating can help. Specifically, sweating due to high-impact exercise, which can lower your biological age by nearly a decade, according to researchers. The study, conducted at Brigham Young University and published in the Preventive Medicine medical journal, looked at the data of more than 5,800 adults aged 20-84. The study looked at the participants' biological age by examining the length of their telomeres — these are the protective DNA caps at the end of chromosomes. Telomeres prevent your DNA from getting damaged; they shorten as we get older, and shortened telomeres are often associated with age-related diseases. The measurement is taken through blood samples. The researchers found that people who consistently performed high levels of physical activity, specifically high-impact activity, had longer telomeres than those with sedentary lifestyles. For the study, to be highly active, women had to engage in 30 minutes of jogging per day and 40 minutes for men, five days a week. They concluded that regular high-impact exercise added nine years of reduced cellular aging. 'If you want to see a real difference in slowing your biological aging, it appears that a little exercise won't cut it,' exercise science professor Larry Tucker said. 'You have to work out regularly at high levels.' If you're new to jogging, it can be difficult to know where to start. Mixing jogging with walking intervals as you get fitter and build up your distance, also known as Jeffing, can be beneficial. Here's everything you need to know about Jeffing, and a round-up of the best running shoes on the market. That said, if you're not a runner or you're worried about the impact of running on your joints, high-intensity training doesn't have to involve pounding the sidewalk or hours on the treadmill. HIIT training, cycling sprints on a stationary bike, taking a spin class, or using the rowing machine in the gym all count as high-intensity exercise. Find the one that works for you, and you'll increase your cardiovascular fitness while lowering your biological age. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button. More from Tom's Guide Forget running and swimming — study finds this sport adds 10 years to your life Forget gym machines — study shows this type of exercise is the most effective at building strength, muscle and power Forget 10,000 steps — study reveals the real number of minimum daily steps you should take, according to your age
Yahoo
an hour ago
- Yahoo
Sun Blasts Powerful X1.2-Class Solar Flare
Watch footage of the Sun unleashing an X1.2-class solar flare. NASA's Solar Dynamics Observatory captured the fireworks in multiple wavelengths. Footage courtesy: NASA / SDO and the AIA, EVE, and HMI science teams, Helio Viewer | edited by Steve Spaleta Solve the daily Crossword
